Business & Investment

U.S. suspends use of J & J’s COVID-19 vaccine following reports of rare blood clots

US regulators have temporarily stopped using Johnson & Johnson’s COVID-19 vaccine and are investigating six serious cases of rare blood clots reported in people who received the shot.

J & J shares
JNJ,
-2.40%

Trading on Tuesday fell 2.4%.

In a joint statement, the Centers for Disease Control and Prevention and the Food and Drug Administration said there were six cases of cerebral venous sinus thrombosis. One person has died and the other is in serious condition, according to a statement made by FDA officials on Tuesday.

This is thought to be related to blood coagulation disorders, but it occurs rarely. Six out of about 6.8 million people in the United States are vaccinated with this vaccine.

“We recommend that you take great care to suspend the use of this vaccine,” health officials said on Tuesday.

“We are working closely with healthcare professionals and health authorities,” J & J said in a statement. The company also said in the same statement that it would “aggressively delay the deployment of vaccines in Europe.” (J & J’s COVID-19 was approved in Europe in mid-March.)

AstraZeneca
AZN,
+ 0.08%

AZN,
-0.08%

The COVID-19 vaccine, which is not licensed in the United States, faces similar concerns about rare blood clots, and some European countries have stopped using the vaccine.Austrian and German researchers last week Linked thrombi reported in Europe to AstraZeneca vaccine, Instances are referred to as “vaccine-induced immune thrombotic thrombocytopenia”.

Both the AstraZeneca and J & J vaccines are adenovirus vaccines, unlike the mRNA vaccine developed by BioNTech SE.
BNTX,
+ 5.59%

/Pfizer Japan Inc
PFE,
+ 0.51%

And Moderna Inc.
MRNA,
+ 7.64%
..

All six US cases of blood clots after vaccination occurred in women aged 18-48 years within 6-13 days of firing.

The CDC Vaccination Implementation Advisory Committee, which recommends the use of vaccines after approval by the Food and Drug Administration, will meet on Wednesday to review cases. One of the reasons for the suspension is to ensure that your healthcare provider is ready to treat the blood clot in the event of a blood clot.

“this [meeting] Given the current state of the COVID-19 pandemic in the United States and the broader vaccination efforts, we will carefully consider what we know about these events and consider the next steps. ” Said Dr. Anne Schuchat, Chief Deputy Director of the CDC. I told reporters on Tuesday.

She added that if someone was vaccinated with the J & J vaccine a month ago, that person is likely to have a lower risk of developing the disorder. If you received this shot last month, you should be aware of symptoms such as severe headaches, abdominal pain, lower limb pain, and shortness of breath.

J & J shares are down 0.3% from the beginning of the year, S & P 500 is broader
SPX,
+ 0.09%

It has increased by 9.9%.

U.S. suspends use of J & J’s COVID-19 vaccine following reports of rare blood clots

http://www.marketwatch.com/news/story.asp?guid=%7B21005575-02D4-D4B5-4572-D381DB85B124%7D&siteid=rss&rss=1 U.S. suspends use of J & J’s COVID-19 vaccine following reports of rare blood clots

Back to top button